Document:

Joint Development Agreement

 Exhibit 10.22 
 ***Text Omitted and Filed Separately 
 with the Securities and Exchange
Commission. 
 Confidential Treatment Requested 
 Under 17 C.F.R. Sections 200.80(b)(4) 
 and 230.406 

JOINT DEVELOPMENT AGREEMENT 
 This Joint Development Agreement (this “JDA”), is dated as of this 15th day of April, 2011 (“Effective Date”), by and between Genomatica, Inc., a Delaware corporation with
principal offices located at 10520 Wateridge Circle, San Diego, California 92121 (hereinafter referred to as “Genomatica”), and Chemtex Italia S.r.l., an Italian corporation with principal offices located at Strada Ribrocca n. 11,
15057 Tortona (AL), Italy (hereinafter referred to as “Chemtex”). 
 RECITALS: 

WHEREAS, Genomatica has invented and developed proprietary technology and recombinant microorganisms to produce
1,4-butanediol (“Bio-BDO”); 
 WHEREAS, Chemtex has invented and developed the proprietary PROESATM
process, which converts Biomass to cellulosic sugars; 
 WHEREAS, Genomatica and Chemtex have evaluated the economic feasibility
of a biological route for the manufacture of Bio-BDO using Biomass cellulosic sugars; 
 WHEREAS, Genomatica and Chemtex
mutually desire to join their respective strengths in a relationship for the joint development of a process combining their respective processes for producing renewable Bio-BDO from Biomass feedstocks; and 

WHEREAS, each Party recognizes it may be necessary or desirable to grant to the other Party access to certain intellectual property in
order to carry out the objectives of this JDA. 
 NOW THEREFORE, Genomatica and Chemtex agree to the following terms and conditions: 

ARTICLE I 

DEFINITIONS 
 1.1. Previously Defined Terms. Each term defined in the preamble and the Recitals to this JDA shall have the meaning set forth above whenever used herein. 

1.2. Definitions. In addition to the terms defined in the preamble and the Recitals of this JDA, the following terms, whenever
used herein, shall have the meanings set forth below: 
 1.2.1. “Affiliate” shall mean, with respect to any
specified Person, any other Person that directly, or indirectly through one or more intermediaries, controls, is controlled by, or is under common control with, such specified Person, and for this

  

			
	1	  	

 
purpose, “control,” “controlled by” and “common control” shall mean the ownership and voting control of more than 50% of the outstanding voting securities or
interest in capital or profits of such specified Person, or the right to direct or control the management or affairs of such specified Person by contract or similar arrangement. Should a Person divest an Affiliate or should an Affiliate cease to
satisfy this definition, such Affiliate’s rights and obligations under this JDA shall be terminated. 
 1.2.2.
“Background Intellectual Property” shall mean all Intellectual Property first conceived, reduced to practice and/or otherwise acquired or obtained by a Party prior to the Effective Date of this JDA or outside of the course of the
Joint Development Program and during the term of this JDA, including rights arising in the course of prosecution and maintenance of such Intellectual Property, which such Party discloses or otherwise provides to the other Party for use in the Joint
Development Program. 
 1.2.3. “Bio-BDO Field” shall mean the biological manufacture of Bio-BDO from sugars
produced from Biomass and the marketing and the sale of Bio-BDO manufactured from sugars produced from Biomass, and includes research and development related to the foregoing. 
 1.2.4. “Biomass” shall mean any non-food agriculture plant (such as but not limited to poplar, eucalyptus and energy crops) and agricultural waste (such as but not limited to straw, corn
stover and sugar cane bagasse) that can be used as a renewable non-food feedstock for the production of sugars (which non-food feedstock excludes, without limitation, first generation food feedstocks of corn, wheat, sugar beets and sugar cane).

 1.2.5. “Bioprocess” shall mean a fermentation process using microorganisms for the production of Bio-BDO,
and including the downstream Bio-BDO purification steps. 
 1.2.6. “Chemtex Confidential Information” shall
mean any Confidential Information of Chemtex. 
 1.2.7. “Chemtex Intellectual Property” shall mean (a) all
Background Intellectual Property owned or licensed (with the right to grant licenses or sublicenses) by Chemtex which claims or covers all or part of the PROESATM Process Technology, and (b) all JDA Intellectual Property owned by Chemtex.

 1.2.8. “Commercialization KPIs” shall have the meaning set forth in Section 3.1(b). 

1.2.9. “Commercial Process” shall have the meaning set forth in Section 2.1. 

1.2.10. “Confidential Information” shall mean any and all proprietary information and materials, in any form (written,
oral, photographic, electronic, magnetic, or otherwise), including without limitation, information related to technical, business, and 

  

			
	2	  	

 
intellectual property matters, intellectual property including know-how, data, trade secrets, and all documents and other physical materials relating to prototypes, materials, compositions,
devices, methods, or procedures related to the research and development, manufacture, use or sale of Bio-BDO. Confidential Information of a Party disclosed pursuant to the NDA shall be treated as Confidential Information under this JDA. The Chemtex
Intellectual Property shall be Confidential Information of Chemtex, and the Genomatica Intellectual Property shall be Confidential Information of Genomatica. 
 1.2.11. “Damages” shall have the meaning set forth in Section 13.1. 
 1.2.12. “Development Plan” shall mean the plan for activities to be conducted under the Joint Development Program which is set forth in Schedule 1.2.12, including deliverables, estimated
timelines and budget, which may be amended by the JDC pursuant to Section 5.2. 
 1.2.13. “Facilities”
shall mean the Chemtex facilities located in Rivalta Scrivia (AL) – Italy. 
 1.2.14. “Genomatica Confidential
Information” shall mean any Confidential Information of Genomatica. 
 1.2.15. “Genomatica Intellectual
Property” shall mean (a) all Background Intellectual Property owned or licensed (with the right to grant licenses or sublicenses) by Genomatica, which claims or covers all or part of a Bioprocess, including the components (including
Genomatica Microorganisms) used in a Bioprocess, (b) all Process Intellectual Property, and (c) all JDA Intellectual Property owned by Genomatica. 
 1.2.16. “Genomatica Microorganism(s)” shall mean microorganisms designated by Genomatica and identified in Schedule 1.2.16 and which may be supplied by Genomatica during the term of the
Joint Development Program. 
 1.2.17. “Intellectual Property” shall mean all (a) Patent Rights,
(b) trademarks, service marks, domain names, trade dress, logos, trade names, and corporate names and registrations and applications for registration thereof, (c) copyrights and registrations and applications for registration thereof,
(d) computer software, data, and documentation, (e) trade secrets and confidential business information, whether patentable or unpatentable and whether or not reduced to practice, know-how, manufacturing and production processes and
techniques, research and development information, copyrightable works, financial, marketing and business data, pricing and cost information, business and marketing plans and customer and supplier lists and information, (f) other proprietary
rights relating to any of the foregoing, and (g) copies and tangible embodiments thereof. 
 1.2.18. “JDA
Intellectual Property” shall mean all Intellectual Property first conceived, reduced to practice and/or otherwise acquired or obtained solely by a Party or jointly by the Parties in the course of and during the term of the Joint

  

			
	3	  	

 
Development Program, including rights arising in the course of prosecution and maintenance of such Intellectual Property, but excluding all Process Intellectual Property. 

1.2.19. “Joint Development Committee” or “JDC” shall mean the joint committee established pursuant to
Article V. 
 1.2.20. “Joint Development Program” shall mean the joint program undertaken by the Parties under
this JDA as described in Articles II and III. 
 1.2.21. “Law” shall mean any federal, state, regional, local,
or foreign law, constitution, rule, statute, ordinance, regulation, order, code, judgment, charge, writ, injunction, or decree. 

1.2.22. “MOU” shall have the meaning set forth in Section 1.2.32. 

1.2.23. “NDA” shall mean the nondisclosure agreement between the Parties dated 19 March 2010 between M&G
Finanziaria S.r.l. and Genomatica and covering also M&G Finanziaria Affiliates, which includes Chemtex. 
 1.2.24.
“Party” shall mean Genomatica or Chemtex, as the case may be, and “Parties” shall mean Genomatica and Chemtex. 
 1.2.25. “Patent Rights” shall mean any patent application, certificate of invention, application for certificate of invention, priority patent filing or patent (foreign or domestic),
including any and all divisionals, continuation (in whole or in part), request for continued examination, reissues, reexaminations, additions, substitution cases, confirmations, registrations, revalidations, revisions, renewals and extensions
thereof. 
 1.2.26. “Person” shall mean an individual or a corporation, partnership, limited liability company,
trust, incorporated or unincorporated association, joint venture, joint stock company, government (or an agency or political subdivision thereof) or other entity of any kind. 
 1.2.27. “Pilot Phase” shall have the meaning set forth in Section 2.2. 
 1.2.28. “Pilot Plant Facility” shall have the meaning set forth in Section 2.1. 
 1.2.29. “Process Intellectual Property” shall mean all Intellectual Property relating to all or part of a Bioprocess, including any components (including microorganisms) used in a
Bioprocess, and/or the basic engineering package that uses or incorporates the Bioprocess, which Intellectual Property is first conceived, reduced to practice and/or otherwise acquired or obtained solely by a Party or jointly by the Parties in the
course of and during the term of the Joint Development Program, including rights arising in the course of prosecution and maintenance of such Intellectual Property. For clarification, Process Intellectual Property excludes all Background
Intellectual Property. 

  

			
	4	  	

 1.2.30. “PROESATM Intellectual Property” shall mean all Intellectual
Property relating to all or part of PROESATM Process Technology, including any components used in PROESATM Process Technology, and/or the basic engineering package that uses or incorporates the PROESATM Process Technology, which
Intellectual Property is first conceived, reduced to practice and/or otherwise acquired or obtained solely by a Party or jointly by the Parties in the course of and during the term of the Joint Development Program, including rights arising in the
course of prosecution and maintenance of such Intellectual Property. For clarification, PROESATM Intellectual Property excludes all Background Intellectual Property. 
 1.2.31. “PROESATM License” shall have the meaning set forth in Section 3.3. 
 1.2.32. “PROESATM License Agreement” shall mean the license in the Bio-BDO Field granted by Chemtex to Genomatica for the use of the PROESATM Technology, PROESATM Intellectual
Property and Chemtex Intellectual Property in the Commercial Process where the scope of the license and the applicable conditions are as set out in the “Biomass to Chemicals Partnership Memorandum of Understanding (MOU)” between Genomatica
and Gruppo M&G dated February 14, 2011 (hereinafter referred to as the “MOU”). The MOU is attached hereto as Schedule 1.2.36. 
 1.2.33. “PROESATM Process Technology” shall mean the process configuration, operating parameters and conditions, the equipment set up and/or the equipment design to produce
fermentable sugar or precursor of fermentable sugar from Biomass [...***...]. For clarification, PROESATM Process Technology does not include any technology (including, but not limited to, process configuration, operating parameters and
conditions, equipment set up and/or equipment design) with respect to any portion of a process using fermentable sugar, including, without limitation, any process for fermentation of fermentable sugars. 

1.2.34. “Representatives” shall mean, with respect to any Person, the directors, officers, employees, agents,
Affiliates, or other representatives of such specified Person, including, without limitation, financial advisors, consultants, and counsel. 
 1.2.35. “Territory” shall mean the world. 
 1.2.36.
“Third Party(ies)” shall mean any Person other than Genomatica and its Affiliates or Chemtex and its Affiliates. 
 1.2.37. “Third Party Agreement” shall have the meaning set forth in Section 3.3. 

  

			
	 5
  
	  	***Confidential Treatment Requested

 ARTICLE II 
 JOINT DEVELOPMENT PROGRAM OBJECTIVES 
 2.1. Objectives. The purpose
of the Parties’ relationship under this JDA is to further develop Genomatica’s current Bioprocess at the Chemtex’s PROESATM pilot plant located at the Facilities (the “Pilot Plant Facility”) to produce Bio-BDO
from cellulosic sugars produced from Biomass feedstocks by modifying the Pilot Plant Facility to develop Genomatica’s current Bioprocess into a continuous or semi-continuous commercially viable Bioprocess for producing Bio-BDO from cellulosic
sugars generated using Biomass feedstocks via PROESATM Process Technology (collectively, the “Commercial Process”) at a competitive cash cost relative to petroleum-based BDO. The Parties also desire to discuss options to work
together to commercialize in the Territory, Bio-BDO produced using the Commercial Process and Biomass feedstocks at a commercial manufacturing facility co-located with a Third Party. 

2.2. Pilot Phase. During the period of performance of the Joint Development Program (the “Pilot Phase”), the
objective is to demonstrate the ability to manufacture Bio-BDO via the Bioprocess using cellulosic sugars generated from Biomass feedstocks via the PROESATM Process Technology in the Pilot Plant Facility. The principal tasks in the Pilot Phase
shall consist of those matters set forth in the Development Plan. 
 ARTICLE III 

PILOT PHASE 
 3.1. Pilot Phase. 
 (a) During the Pilot Phase, the
responsibility of the Parties for costs and expenses will be as set forth in Schedule 3.1(a). Without the approval of the JDC, neither Party will incur any capital expenditures in the performance of the Pilot Phase except as expressly set forth in
the Development Plan. 
 (b) [...***...]. The JDC will determine whether the technical and commercial key
performance indexes (KPIs) for the Pilot Phase, as set forth in the Development Plan (the “Commercialization KPIs”) have been satisfied. The Pilot Phase will continue until the date that the principal tasks in the Development Plan
(and any other tasks reasonably determined by Genomatica) have been completed, whether or not the Commercialization KPIs have been satisfied. 
 3.2. Deliverables. 
 3.2.1. Genomatica Deliverables. 

(a) During the Pilot Phase, Genomatica will be responsible for (i) transferring to the Pilot Plant Facility
[...***...] which will be subject to review by Chemtex, with the [...***...] approved by the JDC and will comply with safety and environmental standards 

  

			
	 6
  
	  	***Confidential Treatment Requested

 
required for activities conducted at the Pilot Plant Facility, and (ii) completing the [...***...], in each case subject to having sufficient data regarding the Pilot Plant Facility to
enable such activities. 
 (b) During the Pilot Phase, Genomatica will be responsible for providing information
regarding Genomatica’s actual Bioprocess costs for use in jointly developed cost models,which are currently cost advantaged relative to petroleum-based BDO plant costs, using dextrose. These costs will be subject to review by Chemtex, through
the JDC. 
 3.2.2. Chemtex Deliverables. 

(a) During the Pilot Phase, Chemtex will be responsible [...***...]. 

(b) During the Pilot Phase, Chemtex will be responsible for the following: 

(i) providing Biomass feedstock to produce cellulosic sugars; 

(ii) providing engineering and manufacturing expertise and experience to [...***...]; and 

(iii) providing Bio-BDO product support services, including [...***...]. 

(c) During the Pilot Phase, Chemtex will be responsible for providing information regarding Chemtex’s actual cost for
PROESATM Process Technology based upon a Biomass standard cost of [...***...] $/t d.m. for use in jointly developed cost models. These costs will be subject to review by Genomatica, through the JDC. 

3.2.3. Joint Deliverables. The Parties will be jointly responsible for the following deliverables under the Development Plan:

 (a) jointly developing the overall process cost model, including the PROESATM cellulosic sugar cost model
and the Bio-BDO cost model, that is required to manufacture competitive Bio-BDO; and 
 (b) preparing the PDP for
the overall process on the basis of the result of the Pilot Phase, and 
 (c) coordinating any external
communications regarding the Development Plan. 

  

			
	 7
  
	  	***Confidential Treatment Requested

 3.3. Commercialization Structure. During the Pilot Phase, the Parties will discuss
how to work together to commercialize Bio-BDO in the Territory using the Commercial Process. [...***...]. 
 ARTICLE IV

 COMMERCIALIZATION 
 4.1. Commercialization Process License. Upon completion of the Pilot Phase, provided that the Bio-BDO produced in the Pilot Phase meets minimum standards of quality and costs, applicable to
petroleum-based BDO, which specifications are described on Schedule 4.1, Genomatica will enter into Third Party Agreement discussions and provide written notice to Chemtex identifying the potential Third Party licensee. Genomatica will bear
all expenses it incurs in executing Third Party Agreements. 
 4.2. Negotiation of PROESATM License Agreement. The
Parties will negotiate in good faith the definitive agreements for the PROESATM License Agreement for the commercialization of Bio-BDO produced using the Commercial Process, including the PROESATM Process Technology, in the Territory.

 4.3. Supply of Biomass Feedstock. [...***...]. 

ARTICLE V 

GOVERNANCE OF THE JOINT DEVELOPMENT PROGRAM 
 5.1. Formation of Joint Development Committee (JDC). Promptly following the Effective Date, the Parties shall form the JDC, and each Party will appoint two of its employees to serve on the JDC. The
purpose of the JDC is to oversee, guide, and monitor the conduct of the Joint Development Program under the terms of this JDA. To ensure the success of the Joint Development Program, the JDC will meet regularly and at least quarterly to review the
progress towards the objectives of the Joint Development Program. Such meetings may be held in person, or by any means of telecommunications 

  

			
	 8
  
	  	***Confidential Treatment Requested

 
or video conference, as the JDC members deem necessary or appropriate. The JDC will keep minutes of its meetings, including at a minimum who is in attendance, the subject matter discussed or
considered, and any action taken. Decisions of the JDC will be made by unanimous approval, with the representatives of Genomatica collectively having one vote and the representatives of Chemtex collectively having one vote. If the JDC is unable to
reach agreement on any matter properly before it, then either Party may, by written notice to the other Party, have such matter referred for resolution pursuant to Section 14.14. 

5.2. Responsibilities of JDC. The JDC shall have the following responsibilities and authority: 

 

	 	(a)	to provide a means of communication between the Parties regarding the Joint Development Program; 

 

	 	(b)	subject to and within the parameters of the Development Plan, to monitor and oversee the implementation of the Development Plan; 

 

	 	(c)	to review and approve any amendments or modifications to the Development Plan; and 

 

	 	(d)	such other responsibilities as expressly assigned to the JDC under this JDA or by written agreement of the Parties. 

5.3. Reservation of Rights. Matters outside the scope of the Joint Development Program and internal to each Party are not under
the purview of the JDC. Such matters include but are not limited to internal personnel policies and programs, budgeting, finance, commercial and marketing strategies, and business decisions. However, the Parties agree to communicate with each other
promptly on those matters which, while outside the scope of the Joint Development Program, nevertheless may reasonably be expected to affect the Joint Development Program. 
 5.4. Independent Contractors. Each party is an independent contractor and shall retain complete control and responsibility for its own operations and employees. Nothing in this JDA shall be
construed to constitute either Party as a partner, agent or representative of the other Party. Neither Party shall have the right or authority to assume or create any obligation on behalf of or in the name of the other, or to bind the other in any
manner whatsoever. 
 ARTICLE VI 
 ADDITIONAL OBLIGATIONS OF CHEMTEX 
 6.1. Supply of Storage Equipment and
Instrumentation. Chemtex shall supply [...***...]. 

  

			
	 9
  
	  	***Confidential Treatment Requested

 6.2. Installation of Equipment and Instrumentation. Chemtex shall coordinate the
installation of all equipment and instrumentation (including any Genomatica-supplied equipment or instrumentation) at the Facilities. The equipment and instrumentation, together with the Facilities, shall be accessible, upon reasonable prior notice,
to Genomatica employees assigned to support the Joint Development Program. 
 6.3. Services. Chemtex shall supply
(i) technical and engineering services for the Facilities and (ii) employees to operate the Facilities. 
 6.4.
Access to Information and Data. Chemtex shall provide Genomatica reasonable access to all Confidential Information, technical information, and data used during and data generated from the startup and operation of the Facilities. 

ARTICLE VII 

ADDITIONAL OBLIGATIONS OF GENOMATICA 
 7.1. [...***...]. During the Pilot Phase and in accordance with the Development Plan, Genomatica shall [...***...] pursuant to this JDA. 

7.2. [...***...]. [...***...] required to be supplied by Genomatica under the Development Plan as well as
[...***...] defined in detail in the Development Plan. 
 7.3. Availability of Technical Employees. Genomatica
shall make available such technical employees at the Facilities reasonably required by Chemtex to assist in the development of the Bioprocess as provided in the Development Plan. Genomatica shall cause its employees to comply with Chemtex’s
safety, health, and environmental policies and procedures. 
 ARTICLE VIII 

INTELLECTUAL PROPERTY 
 8.1. Background Intellectual Property. Each Party acknowledges and agrees that, as between the Parties, each Party is and shall remain the sole and exclusive owner of all right, title, and interest
in and to its Background Intellectual Property, and that this JDA does not affect such ownership. Each Party acknowledges that it acquires no rights under this JDA to the other Party’s Background Intellectual Property other than the limited
rights specifically granted in this JDA. 
 8.2. Process Intellectual Property. All Process Intellectual Property, other
than the PROESATM Intellectual Property, will be owned by Genomatica. Chemtex hereby irrevocably transfers, conveys and assigns to Genomatica all of its right, title, and interest in the Process Intellectual Property, other than the PROESATM
Intellectual Property, and agrees to execute such documents, render such assistance, and take such other action as Genomatica may reasonably request, at Genomatica’s expense, to apply for, register, perfect, confirm, and protect
Genomatica’s ownership rights in such Process Intellectual 

  

			
	 10
  
	  	***Confidential Treatment Requested

 
Property. The Parties shall use commercially reasonable efforts to promptly disclose and jointly identify all Process Intellectual Property during the term this JDA. Under the PROESATM
License Agreement, Chemtex will grant to Genomatica the exclusive right under the Chemtex Intellectual Property and PROESATM Intellectual Property to use the PROESATM Process Technology with and as part of the Commercial Process. Chemtex
shall render such assistance, and take such other action as Genomatica may reasonably request, to protect Genomatica’s license rights in the Chemtex Intellectual Property and PROESATM Intellectual Property. 

8.3. JDA Intellectual Property. JDA Intellectual Property first conceived or reduced to practice solely by employees and/ or
consultants of a Party shall be owned solely by such Party, and JDA Intellectual Property first conceived or reduced to practice jointly by employees and/or consultants of both Parties shall be owned [...***...]. A Party shall have the
exclusive right to apply for or register any patents and other proprietary protections with respect to the JDA Intellectual Property solely owned by such Party, including, for example, improvements, modifications, or uses of existing technology in
different areas. The Parties through the JDC shall agree which Party shall apply for and register any patents and other proprietary protections with respect to the [...***...], and shall cooperate in such activities, including sharing copies
of filings with adequate time for review and comment by the other Party, and assembling inventorship information and data for filing such patent applications. Each Party shall have the right to use and practice, and grant licenses to use and
practice, all [...***...], without the consent of or any duty of accounting to the other Party; provided that Chemtex shall not have the right to use and practice, or grant licenses to use and practice, [...***...] for the development,
production, sale and distribution of BDO; and provided that Genomatica shall not have the right to use and practice, or grant licenses to use and practice, [...***...]. 
 8.4. No Implied Licenses. No license or right is granted by implication or otherwise with respect to any patent application or patent except as may be specifically set forth in this JDA. Chemtex
and Genomatica will promptly notify the other in writing if such Party (a) becomes aware of any Intellectual Property of a Third Party that would be infringed by the activities under the Joint Development Program, (b) receives a written
claim or notice of infringement of any Intellectual Property of a Third Party related to the activities under the Joint Development Program or (c) is sued for infringement of any Intellectual Property of a Third Party as a result of the
activities under the Joint Development Program. 
 ARTICLE IX 

GRANT OF RIGHTS 
 9.1. Limited License for Joint Development Program. Subject to the terms and conditions of this JDA, Genomatica hereby grants to Chemtex a non-exclusive, non-sublicensable (except to Chemtex’s
Affiliates), royalty-free license to use Genomatica Intellectual Property directly relevant to the Joint Development Program within the Pilot 

  

			
	11	  	  
 ***Confidential Treatment
Requested

 
Plant Facility, solely for purposes of performing Chemtex’s obligations under the Joint Development Program during the term of this JDA. Subject to the terms and conditions of this JDA,
Chemtex hereby grants to Genomatica a non-exclusive, non-sublicensable (except to Genomatica’s Affiliates), royalty-free license to use Chemtex Intellectual Property and PROESATM Intellectual Property directly relevant to the Joint
Development Program within the Territory solely for purposes of performing Genomatica’s obligations under the Joint Development Program during the term of this JDA. If a Party grants a sublicense of the license under this Section 9.1 to
any of its Affiliates, such Party shall cause its Affiliates to comply with all obligations of such Party hereunder, including, without limitation, Articles VIII and X; provided that such Party shall at all times be fully responsible for the
performance of such Affiliate. 
 9.2. Reservation of Rights to Intellectual Property. Chemtex reserves all rights under
the Chemtex Intellectual Property and PROESATM Intellectual Property, subject only to the license granted to Genomatica in Section 9.1, and Genomatica reserves all rights under the Genomatica Intellectual Property, subject only to the
licenses granted to Chemtex in Section 9.1. Notwithstanding anything to the contrary in this JDA, the Parties acknowledge and agree that general knowledge about operation of the Facilities learned or observed in the course of the Joint
Development Agreement may be used by either Party. 
 9.3. Mutual Agreements. Chemtex agrees not to practice the
Genomatica Intellectual Property and the JDA Intellectual Property developed jointly by the Parties, and Genomatica agrees not to practice the Chemtex Intellectual Property, PROESATM Intellectual Property and the JDA Intellectual Property
developed jointly by the Parties, in each case except as expressly permitted in this JDA or other written agreement between the Parties. 
 9.4. No Use of Names. Except as otherwise provided herein, no right, express or implied, is granted by this JDA to use in any manner the name “Chemtex” or “Genomatica” or any
other trademark, service mark, or trade name of the other Party in connection with the performance of this JDA. 
 ARTICLE X

 CONFIDENTIAL INFORMATION 
 10.1. Confidentiality. Each Party (in such capacity, the “receiving Party”) agrees to maintain the confidentiality of, and not disclose to any other Person, all Confidential Information
of the other Party (in such capacity, the “disclosing Party”) and not to use the Confidential Information of the other Party except for the purposes of this JDA or pursuant to the terms of a Commercialization Agreement, in each case for
[...***...] from the Effective Date of this JDA. The obligation of confidentiality, nondisclosure and nonuse shall not apply to Confidential Information which: 
  

	 	(a)	is or becomes public through no fault of the receiving Party; 

  

			
	12	  	  
 ***Confidential Treatment
Requested

	 	(b)	is known by the receiving Party at the time of disclosure as shown by prior written records; 

 

	 	(c)	is disclosed to the receiving Party by a Third Party entitled to disclose it without obligation of confidentiality, [...***...] 	 

  

	 	(d)	[...***...]. 

 10.2.
Permitted Disclosures. Each Party may disclose Confidential Information belonging to the other Party: 

(a) to its own employees or consultants who are subject to binding obligations concerning confidential information and
inventions, to the extent such disclosure is reasonably necessary in connection with the activities contemplated by this JDA, provided that the disclosing Party shall be responsible for any breach thereof by its own employees or consultants;

 (b) to the extent such disclosure is reasonably necessary for filing or prosecuting patents as expressly
permitted by Article VIII; or 
 (c) to the extent such disclosure is reasonably necessary for prosecuting or
defending litigation or complying with applicable laws, rules or governmental regulations, providing that in the event a Party is required to make a disclosure of the other Party’s Confidential Information pursuant to this clause (c), it shall,
except where impracticable or not permitted by Law, give reasonable advance notice to the other Party of such disclosure and use commercially reasonable efforts, at the cost of the other Party, to secure confidential treatment of such information.

 10.3. Permitted Disclosure of Material Terms of this JDA. A Party shall have the right to disclose the material terms
of this JDA (a) to any Person retained by such Party to perform legal, accounting, engineering or similar services and who have a need to know such terms in order to provide such services and (b) to Third Parties in connection with due
diligence or similar investigations by such Third Parties, provided that any such Person or Third Party is bound to confidentiality obligations consistent in all material respects with the terms of this Article X. 

10.4. Publicity. In any event, each Party agrees to take all reasonable action to avoid disclosure of the other Party’s
Confidential Information hereunder. Promptly following the Effective Date, the Parties will coordinate issuing a press release concerning this JDA (which may be a joint press release or separate press releases by each Party), subject to mutual
agreement of the Parties on the content of such press release. If either Party desires to, or is required by Law or stock exchange requirements to, make a public announcement concerning this JDA or the subject matter hereof after such initial press
release, such Party shall give reasonable prior advance notice of the proposed text of such announcement to the other Party for its prior review and comment. 

  

			
	13	  	  
 ***Confidential Treatment
Requested

 10.5. JDA Terms Are Confidential Information of Both Parties. Except for public
statements agreed to by the Parties or for disclosures that are in the reasonable judgment of a Party required by Law or stock exchange listing requirements, the Parties agree that the existence, material terms, and the subject matter of this JDA
shall be considered Confidential Information of both Parties. 
 10.6. Equitable Remedies. Each Party acknowledges and
agrees that the other Party’s remedies at law for breach or threatened breach of any of the provisions of this Article 10 would be inadequate and, in recognition of that fact, in the event of any such breach or threatened breach, it is agreed
that, in addition to other remedies to which it may be entitled, the other Party will be entitled to equitable relief in the form of specific performance, temporary restraining order, temporary or permanent injunction without the necessity of
posting bond, or any other equitable remedy which may then be available; provided, that nothing herein contained will be construed as prohibiting the non-breaching Party from pursuing any other remedies available to it for such breach or threatened
breach, including recovery of damages from such breaching Party. 
 ARTICLE XI 

REPRESENTATIONS AND WARRANTIES 
 11.1. Representations and Warranties of Genomatica. Genomatica represents and warrants to Chemtex as of the Effective Date that: 

(a) Genomatica is a corporation, duly incorporated, validly existing and in good standing under the laws of the State of
Delaware. Genomatica has all requisite power and authority to carry on its business and to own and use the assets and properties owned and used by it. 
 (b) Genomatica has all requisite power and authority to execute and deliver this JDA and to perform its obligations hereunder. The execution and delivery of this JDA by Genomatica and the performance by
Genomatica of its obligations hereunder have been duly and validly authorized by all necessary action on the part of Genomatica. This JDA has been duly and validly executed and delivered by Genomatica and, assuming the due authorization, execution
and delivery by Chemtex, constitutes a valid and binding obligation of Genomatica enforceable against Genomatica in accordance with its terms. 
 (c) The execution and delivery of this JDA by Genomatica and the performance by Genomatica of its obligations hereunder, does not and will not, as the case may be, (i) conflict with or violate any
provision of the Certificate of Incorporation or the Bylaws of Genomatica, (ii) conflict with, result in a breach of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration of, create in any
party the right to accelerate, terminate, modify or cancel, or require any notice, consent or waiver under, any contract, agreement or arrangement (written or oral), franchise or permit to which Genomatica is a party or by which Genomatica is bound,
(iii) result in the 

  

			
	14	  	

 
imposition of any lien, claim, charge or encumbrance upon any Genomatica Intellectual Property, or (iv) violate any Law applicable to Genomatica. 

(d) There is no action, suit, proceeding, claim, or investigation pending or threatened against Genomatica, in any court
or by or before any governmental authority, or before any arbitrator of any kind, which, if adversely determined, would restrict the ability of Genomatica to perform its obligations hereunder. Genomatica knows of no basis for any such action, suit,
claim, investigation, or proceeding. 
 (e) Genomatica is the exclusive owner of the Background Intellectual
Property included in the Genomatica Intellectual Property, and it has the right to grant Chemtex the limited license under Section 9.1 without conflict with the rights of any Third Party, or has secured all necessary and appropriate consents to
license the same. 
 (f) The Background Intellectual Property included in the Genomatica Intellectual Property is
not subject to any claims, encumbrances, liens, licenses, judgments and/or security interests that could reasonably be expected to have an adverse effect on the right to practice such Background Intellectual Property in the Bio-BDO Field, and none
of the Background Intellectual Property included in the Genomatica Intellectual Property is the current subject of any litigation, interference or opposition proceeding. 

(g) Genomatica is unaware of any publications or activities (including, without limitation, patents, articles, and public
uses or sales) by it or others, which could reasonably be expected to invalidate any claim(s) of any patent or patent application within the Background Intellectual Property included in the Genomatica Intellectual Property. 

(h) Genomatica is not aware of any valid Third Party Intellectual Property that could reasonably be expected to be
infringed or asserted to be infringed by practice of the Background Intellectual Property included in the Genomatica Intellectual Property in the performance of the Joint Development Program pursuant to this JDA. 

(i) Genomatica has and will continue to have the legal power to extend the rights granted to Chemtex in this JDA with
respect to Process Intellectual Property and JDA Intellectual Property owned by Genomatica, and it has not made and will not make any commitments to others inconsistent with or in derogation of such rights. 

(j) Genomatica has, and will through the term of this JDA, cause its employees who work on the Joint Development Program
to disclose to it inventions within the scope of JDA Intellectual Property or Process Intellectual Property and to assign to it rights in such inventions, it being understood that if 

  

			
	15	  	

 
due care and diligence are used, any inadvertent failure to comply with this Section 11.1(j) will not constitute a breach of this JDA. 

11.2. Representations and Warranties of Chemtex. Chemtex represents and warrants to Genomatica as of the Effective Date that:

 (a) Chemtex is a corporation validly existing and in good standing under the laws of the country of Italy.
Chemtex has all requisite power and authority to carry on its business and to own and use the assets and properties owned and used by it. 
 (b) Chemtex has all requisite power and authority to execute and deliver this JDA and to perform its obligations hereunder. The execution and delivery of this JDA by Chemtex and the performance by Chemtex
of its obligations hereunder have been duly and validly authorized by all necessary action on the part of Chemtex. This JDA has been duly and validly executed and delivered by Chemtex and, assuming the due authorization, execution and delivery by
Genomatica, constitutes a valid and binding obligation of Chemtex enforceable against Chemtex in accordance with its terms. 
 (c) The execution and delivery of this JDA by Chemtex and the performance by Chemtex of its obligations hereunder, does not and will not, as the case may be, (i) conflict with or violate any
provision of the Certificate of Incorporation or By-Laws of Chemtex, (ii) conflict with, result in a breach of, constitute (with or without due notice or lapse of time or both) a default under, result in the acceleration of, create in any party
the right to accelerate, terminate, modify or cancel, or require any notice, consent or waiver under, any contract, agreement or arrangement (written or oral), franchise or permit to which Chemtex is a party or by which Chemtex is bound,
(iii) result in the imposition of any lien, claim, charge or encumbrance upon any Chemtex Intellectual Property, or (iv) violate any Law applicable to Chemtex. 

(d) There is no action, suit, proceeding, or material claim or investigation pending or threatened against Chemtex, in any
court or by or before any governmental authority, or before any arbitrator of any kind, which, if adversely determined, would restrict Chemtex’s ability to perform its obligations hereunder. Chemtex knows of no basis for any such action, suit,
claim, investigation, or proceeding. 
 (e) Chemtex is the exclusive owner of the Background Intellectual
Property included in the Chemtex Intellectual Property, and it has the right to grant Genomatica the limited license under Section 9.1 without conflict with the rights of any Third Party, or has secured all necessary and appropriate consents to
license the same. 
 (f) The Background Intellectual Property included in the Chemtex Intellectual Property is
not subject to any claims, encumbrances, liens, licenses, 

  

			
	16	  	

 
judgments and/or security interests that could reasonably be expected to have an adverse effect on the right to practice such Background Intellectual Property in the Bio-BDO Field, and none of
the Background Intellectual Property included in the Chemtex Intellectual Property is the current subject of any litigation, interference or opposition proceeding. 

(g) Chemtex is unaware of any publications or activities (including, without limitation, patents, articles, and public
uses or sales) by it or others, which could reasonably be expected to invalidate any claim(s) of any patent or patent application within the Background Intellectual Property included in the Chemtex Intellectual Property. 

(h) Chemtex is not aware of any Third Party Intellectual Property that could reasonably be expected to be infringed or
asserted to be infringed by practice of the Background Intellectual Property included in the Chemtex Intellectual Property in the performance of the Joint Development Program pursuant to this JDA. 

(i) Chemtex has and will continue to have the legal power to extend the rights granted to Genomatica in this JDA with
respect to Chemtex Intellectual Property, PROESATM Intellectual Property and JDA Intellectual Property owned by Chemtex, and it has not made and will not make any commitments to others inconsistent with or in derogation of such rights.

 (j) Chemtex has, and will through the term of this JDA, cause its employees who work on the Joint Development
Program to disclose to it inventions within the scope of JDA Intellectual Property, PROESATM Intellectual Property or Process Intellectual Property and to assign to it rights in such inventions, it being understood that if due care and diligence
are used, any inadvertent failure to comply with this Section 11.2(j) will not constitute a breach of this JDA. 
 11.3.
Notice of Developments. The Parties will give prompt written notice to each other of (a) any event or development causing a breach of any of their respective representations and warranties contained in this JDA, (b) any failure to
comply with or satisfy any covenant or agreement to be complied with by such Party hereunder and (c) any event or development that, individually or in the aggregate, could reasonably be expected to result in a breach of any of their respective
representations and warranties contained in this JDA or the failure to comply with or satisfy any covenant or agreement to be complied with by such Party hereunder. No disclosure by any Party pursuant to this Section 11.3, however, shall be
deemed to prevent or cure any misrepresentation, breach of warranty or breach of covenant. During the term of this JDA, no Party shall take any action or agree to take any action, either orally or in writing, that could reasonably be expected to
result in a breach of any of their respective representations and warranties contained in this JDA or any failure to comply with or satisfy any covenant or agreement to be complied with by such Party hereunder. 

  

			
	17	  	

 11.4. DISCLAIMER OF WARRANTIES. Except as specifically provided in this Article XI,
each Party disclaims all warranties of any kind, express or implied, to the fullest extent permitted by Law, including but not limited to the implied warranties of merchantability, fitness for particular purpose and noninfringement. NEITHER PARTY
MAKES ANY REPRESENTATION OR WARRANTY WITH REGARD TO THE SUCCESS OF THE JOINT DEVELOPMENT PROGRAM OR THE USEFULNESS OF ANY BACKGROUND INTELLECTUAL PROPERTY, PROCESS INTELLECTUAL PROPERTY OR JDA INTELLECTUAL PROPERTY. 

ARTICLE XII 

INDEMNIFICATION 
 12.1. Indemnification by Genomatica. Genomatica shall indemnify, defend, and hold harmless Chemtex and its Representatives from and against any and all damages, losses, liabilities, judgments,
awards, costs, and expenses of any nature whatsoever, including reasonable attorneys’ fees and court costs (collectively, “Damages”), incurred by any of them as a result of [...***...]. 

12.2. Indemnification by Chemtex. Chemtex shall indemnify, defend, and hold harmless Genomatica and its Representatives from and
against any and all Damages incurred by any of them as a result of [...***...]. 
 12.3. Control of Defense. Except
as specifically provided in this section, any Person entitled to indemnification under this Article XII shall give written notice to the indemnifying Party of any claims that may be subject to indemnification, promptly after learning of such claim,
and the indemnifying Party shall assume the defense of such claims with counsel reasonably satisfactory to the indemnified party. If such defense is assumed by the indemnifying Party with counsel so selected, the indemnifying Party will not be
subject to any liability for any settlement of such claims made by the indemnified party without its consent (but such consent will not be unreasonably withheld or delayed), and will not be obligated to pay the fees and expenses of any separate
counsel retained by the indemnified party with respect to such claims. 
 12.4. Remedies. No remedy set forth in this JDA
is intended to be exclusive of any other remedy. Each remedy shall be in addition to every other remedy provided hereunder, or now or hereafter existing at law, in equity, by statute, or otherwise. 

  

			
	18	  	  
 ***Confidential Treatment
Requested

 ARTICLE XIII 
 TERM AND TERMINATION 
 13.1. Termination by the Parties. This JDA
may be terminated: 
 (a) by mutual written consent of Chemtex and Genomatica; 

(b) by Genomatica in the event Chemtex has breached in any material respect any representation, warranty, covenant or
agreement of Chemtex contained in this JDA, Genomatica has notified Chemtex of the breach, and the breach has continued without cure for a period of thirty (30) days after the notice of breach; 

(c) by Chemtex in the event Genomatica has breached in any material respect any representation, warranty, covenant or
agreement of Genomatica contained in this JDA, Chemtex has notified Genomatica of the breach, and the breach has continued without cure for a period of thirty (30) days after the notice of breach; 

Any termination of this JDA pursuant to Section 13.1 shall be effective upon the delivery of written notice of the terminating Party to the other
Party. 
 13.2. Automatic Termination. This JDA shall automatically terminate, unless the Parties agree otherwise, upon:

 (a) the mutual decision by the Parties to discontinue the Joint Development Program; 

(b) the expiration of five years from the Effective Date; or 

(c) the date on which Genomatica enters into a Third Party Agreement. 

13.3. Effect of Termination. Upon termination of this JDA pursuant to this Article XIII all rights and obligations of the Parties
under this JDA shall terminate, except as provided in this Section 13.3. Upon termination of this JDA, Genomatica shall have the right to remove at its cost any equipment or materials that it has supplied or paid for pursuant to
Section 7.2 hereof, provided that it elects to exercise that right within 60 days after the date of termination. Termination of this JDA shall not relieve or release either Party of any right or obligation which, at the time of such
termination, has already accrued to such Party or which is attributable to a period prior to such termination, nor will any expiration or termination of this JDA preclude either Party from pursuing all rights and remedies it may have under this JDA,
at law or in equity, with respect to breach of this JDA. The provisions set forth in Sections 9.2, 9.3, 9.4, 11.4 and 13.3 and Articles I, VIII, X, XII and XIV shall remain in full force and effect and survive any termination of this JDA. The
expiration or termination of this JDA shall not affect any PROESATM License Agreement entered into prior to such expiration or termination, which shall remain in effect in accordance with its terms. 

  

			
	19	  	

 ARTICLE XIV 
 GENERAL TERMS 
 14.1. Non-Solicitation. During the term of this JDA
and for a period of [...***...] after the termination of this JDA, unless otherwise agreed to by the Parties, each Party agrees that it will not and will not permit its Affiliates to directly or indirectly solicit for employment or consulting
any employee of the other Party or its Affiliates; provided that in no event will listing or advertising any employee or consultant position in any publicly available source or hiring or engaging any person who contacts a Party or its Affiliate
based upon such listing or advertisement be a breach of this Section 14.1. 
 14.2. Force Majeure. The Parties shall
be exempt from liability in respect of any failure to perform their obligations under this JDA due to circumstances beyond their reasonable control, including but not limited to those arising from: (i) war, acts of terrorism, fire, epidemic,
flood or other acts of God, explosion, civil commotion, strike, lock-out or labor disturbances, acts, regulations or laws of any government, or failure of public utilities or common carriers, (ii) inability to procure raw materials due to
shortages of raw materials, or (iii) prevention from or hindrance in obtaining energy or other utilities. The Party so affected shall give written notice to the other Party of any such force majeure event and shall use its good faith efforts to
avoid or remove such causes of non-performance and to continue performance whenever such causes are removed. Should the event(s) of force majeure suffered by a Party extend beyond a three (3)-month period, the other Party may then terminate this JDA
by written notice to the non-performing Party, with the consequences of such termination as set forth in Section 13.3. 

14.3. Notices. Except as expressly set forth to the contrary in this JDA, all notices, requests, or consents provided for
or permitted to be given under this JDA must be in writing and must be given either by depositing that writing in the United States mail, addressed to the recipient, postage paid, and registered or certified with return receipt requested or by
delivering that writing to the recipient in person, by courier, or by facsimile transmission; and a notice, request, or consent given under this JDA is effective on receipt by the person to receive it. All notices, requests, and consents to be sent
to a Party must be sent to or made at the following addresses (or such other address as that a Party may specify by notice to the other Party). 
  

			
	If to Chemtex:	  	Chemtex Italia S.r.l.
		  	Strada Ribrocca n. 11
		  	15057 Tortona (AL) Italy
		  	Attention: Corporate R&D Director
		  	Facsimile: (39) 0131-81-1759

  

			
	20	  	  
 ***Confidential Treatment
Requested

			
	with a copy to:	  	Chemtex International Inc.
		  	1979 Eastwood Road
		  	Wilmington, NC 28403
		  	Attention: General Counsel
		  	Facsimile: (910) 509-4567
		
	If to Genomatica, to:	  	Genomatica, Inc.
		  	10520 Wateridge Circle
		  	San Diego, CA 92121
		  	Attention: Chief Technology Officer
		  	Facsimile: (858) 824-1772
		
	with a copy to:	  	Cooley LLP
		  	4401 Eastgate Mall
		  	San Diego, CA 92121
		  	Attention: Kay Chandler
		  	Facsimile: (858) 550-6420

 Whenever any notice is required to be given by law or this JDA, a written waiver thereof, signed by the person entitled
to notice, whether before or after the time stated therein, shall be deemed equivalent to the giving of such notice. 
 14.4.
Entire Agreement; Superseded. This JDA, together with the Exhibits hereto and the MOU and, as applicable, the PROESATM License Agreement, constitutes the entire agreement of the Parties relating to the subject matter hereof and thereof
and supersedes all prior contracts or agreements with respect to the development of a process for Bio-BDO, whether oral or written, including the NDA. 
 14.5. Effect of Waiver or Consent. A waiver or consent, express or implied, to or of any breach or default by any Party in the performance by that Party of its obligations is not a consent or
waiver to or of any other breach or default in the performance by that Party of the same or any other obligations of that Party. Failure on the part of a Party to complain of any act of any Party or to declare the other Party in default,
irrespective of how long that failure continues, does not constitute a waiver by that Party of its rights with respect to that default until the applicable statute-of-limitations period has run. 

14.6. Amendment or Modification. This JDA may be amended, modified, or supplemented only by a written instrument duly executed by
each of the Parties to, which instrument shall specifically indicate that it is the desire of the Parties to amend, modify or supplement this JDA, and similarly may be waived only by a written instrument duly executed by the waiving Party.

 14.7. Binding Act. This JDA is binding on and inures to the benefit of the Parties and their respective heirs,
legal representatives, successors, and assigns. 

  

			
	21	  	

 14.8. Governing Law. THIS JDA IS GOVERNED BY AND SHALL BE CONSTRUED IN ACCORDANCE
WITH THE LAWS OF THE STATE OF DELAWARE, EXCLUDING ANY CONFLICT-OF-LAWS RULE OR PRINCIPLE THAT MIGHT REFER THE GOVERNANCE OR THE CONSTRUCTION OF THIS JDA TO THE LAW OF ANOTHER JURISDICTION. 

14.9. Severability. If any provision of this JDA or the application thereof to any person or circumstance is held invalid or
unenforceable to any extent, the remainder of this JDA and the application of that provision to other persons or circumstances is not affected thereby and that provision shall be enforced to the greatest extent permitted by Law. 

14.10. Further Assurances. In connection with this JDA and the transactions contemplated hereby, each Party shall execute and
deliver any additional documents and instruments and perform any additional acts that may be necessary or appropriate to effectuate and perform the provisions of this JDA and those transactions. 

14.11. No Third Party Beneficiaries. The provisions hereof are solely for the benefit of the Parties and are not intended to, and
shall not be construed to, confer a right or benefit on any other person. 
 14.12. Counterparts. This JDA may be
executed in any number of counterparts with the same effect as if all signing Parties had signed the same document. All counterparts shall be construed together and constitute the same instrument. 

14.13. Assignability. Unless expressly provided otherwise in this JDA, no Party shall have the right to assign or otherwise
transfer its rights or obligations under this JDA, except with the written consent of the other Party, not to be unreasonably withheld or delayed; provided, however, that a Party may, without the other Party’s consent, assign or otherwise
transfer its rights or obligations under this JDA to (a) a successor in interest to all or substantially all of the business of such Party to which this JDA relates, whether by merger, sale of stock, sale of assets or otherwise, or
(ii) any Affiliate. In the event of any assignment of this JDA by a Party to its Affiliate pursuant to this Section 14.13, the assigning Party shall remain liable and responsible to the non-assigning Party hereto for the performance and
observance of all such rights and obligations by such Affiliate. Any assignment of this JDA in contravention of this Section 14.13 shall be null and void. 
 14.14. Resolutions of Disputes. 
 (a) The Parties will use
commercially reasonable efforts to resolve any dispute through good faith negotiations. If within [...***...] of any dispute being notified to the other Party the dispute has not been satisfactorily concluded, then unless otherwise agreed, the
Parties shall refer the dispute to the Chief Executive Officer of Chemtex and the Chief Executive Officer of Genomatica. If within [...***...] of the dispute being referred to the individuals referenced in the prior sentence the dispute has
not been 

  

			
	22	  	  
 ***Confidential Treatment
Requested

 
satisfactorily concluded, then either Party may (but is not required to) refer the dispute for resolution pursuant to Section 14.14(b). 

(b) Following negotiations pursuant to Section 14.14(a), any remaining dispute, controversy, or claim arising under,
out of or relating to this JDA (and subsequent amendments thereof), its validity, binding effect, interpretation, performance, breach or termination, including tort claims, shall be finally determined by arbitration administered by the American
Arbitration Association under its Commercial Arbitration Rules, as in force at the time when the arbitration is initiated. The arbitral tribunal shall consist of three (3) mutually acceptable arbitrators. The place of arbitration shall be
[...***...]. Judgment on the award rendered by the arbitrators may be entered in any court having jurisdiction thereof. 

14.15. Headings and Recitals. The headings and recitals used herein are for ease of reference and information and do not affect
the interpretation of the Article to which they relate or the interpretation of this JDA in any other respect. 
 14.16.
Limitation of Liability. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER OR ITS AFFILIATES FOR ANY SPECIAL OR CONSEQUENTIAL DAMAGES, REGARDLESS OF THE FORM OF ACTION, WHETHER IN CONTRACT, IN TORT INCLUDING NEGLIGENCE, BY STATUTE OR
UNDER ANY QUASI-CONTRACTUAL THEORY OF LIABILITY, EVEN IF A PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. The foregoing limitations of liability and damages will not apply and nothing in this JDA shall affect either Party’s
liability for breach of any obligation specified in Article X or either Party’s indemnification obligations under Article XII. 
 [signature page follows] 

  

			
	23	  	  
 ***Confidential Treatment
Requested

 IN WITNESS WHEREOF, the Parties caused this Joint Development Agreement to be executed by
their duly authorized and empowered representatives as of the Effective Date. 
  

			
	CHEMTEX ITALIA S.R.L.
		
	By:	 	/s/ Illegible
		
	Title:	 	Chief Technology Officer
	
	GENOMATICA, INC.
		
	By:	 	/s/ William Baum
		
	Title:	 	Executive Chairman

 SIGNATURE PAGE TO JOINT
DEVELOPMENT AGREEMENT 

 SCHEDULE 1.2.12 

DEVELOPMENT PLAN 
 [...***...] 

  

			
		  	  
 ***Confidential Treatment
Requested

 SCHEDULE 1.2.16 

GENOMATICA MICROORGANISMS 
 [...***...] 

  

			
	2.	  	  
 ***Confidential Treatment
Requested

  
 SCHEDULE 1.2.32 
 MOU 

Biomass to Chemicals Partnership 
 Memorandum of Understanding (MOU) 
 (Non-Binding) 

February 14, 2011 
  

 
  

									
		 	

	 		 	

	 	

  
  

The purpose of the MOU is to set forth the basis for a series of Agreements establishing a partnership between Gruppo M&G and Genomatica for the
development and commercialization of process technologies to produce major basic and intermediate chemicals from biomass. This MOU is intended by the parties to be non-binding, does not contain all of the terms necessary to effect the transactions
contemplated hereby, and if the parties wish to proceed with the transaction, the terms of any such agreements effecting the transaction shall be embodied in a definitive agreement or agreements. 

[...***...] 

  

			
	3.	  	  
 ***Confidential Treatment
Requested

			
	Gruppo M&G/Genomatica Partnership MOU 	  	

  
  

									
	GRUPPO M&G	 		 	 GENOMATICA, INC.

					
	 Signature:    
	 	  
	 		 	Signature:    	 	  

					
	 Name:
	 	  
	 		 	Name:	 	  

					
	 Title:
	 	  
	 		 	Title:	 	  

					
	 Date:
	 	  
	 		 	Date:	 	  

  

			
	4.	  	

 SCHEDULE 3.1(a) 

RESPONSIBILITY OF PARTIES FOR EXPENSES 
  

			
	 ITEM
	  	Responsibility
	 Genomatica Personnel cost and travelling expenses both in Genomatica lab and in Chemtex Lab
	  	[...***...]
	 Chemtex Personnel cost and travelling expenses both in Genomatica lab and in Chemtex Lab
	  	[...***...]
	 Cost of biomass feedstock for testing and running pilot plant
	  	[...***...]
	 Equipment, instrumentation and installation cost needed to modify the pilot line [...***...]
	  	[...***...]
	 Cost of BDO disposal if not used for testing
	  	[...***...]
	 Cost of preparation of PDP
	  	[...***...]
	 All activities for product storage, testing
	  	[...***...]
	 Sample delivery
	  	[...***...]

  

			
	5.	  	  
 ***Confidential Treatment
Requested

 SCHEDULE 4.1 
 BDO SPECIFICATION 
 [...***...] 

***Confidential Treatment RequestedBGC Holdings, L.P. Seventh Amendment to Agreement of Limited Partnership

 Exhibit 10.1 
 BGC HOLDINGS, L.P. 
 SEVENTH AMENDMENT 

TO AGREEMENT OF LIMITED PARTNERSHIP, 
 AS AMENDED AND RESTATED 
 This Seventh Amendment (this “Seventh Amendment”) to
the Agreement of Limited Partnership of BGC Holdings, L.P. (the “Partnership”), as amended and restated as of March 31, 2008, and as further amended effective as of March 1, 2009, August 3, 2009, January 1,
2010, August 6, 2010, December 31, 2010, and March 15, 2011 (as amended, the “Agreement”), is executed on September 9, 2011 and is effective as of April 1, 2011. 

WITNESSETH: 
 WHEREAS,
the General Partner and the Exchangeable Limited Partner wish to make certain modifications to the Agreement; and 
 WHEREAS, this Seventh
Amendment has been approved by each of the General Partner and the Exchangeable Limited Partner; 
 NOW, THEREFORE, the Agreement is hereby
amended on the terms set forth in this Seventh Amendment: 
  

	Section 1.	Creation and Description of AREUs, ARPUs, APSUs, and APSIs 

 Pursuant to the authority conferred on the General Partner under the Agreement, including without limitation Sections 3.01, 4.02, and 13.01 thereof, there are hereby created new classes of Units in the
Partnership designated as AREUs, ARPUs, APSUs, and APSIs. AREUs, ARPUs, APSUs, and APSIs shall be considered Working Partner Units. 
 AREUs
shall be a separate class of units and otherwise shall be identical in all respects to REUs for all purposes under the Agreement; except that, for as long as, and until, the Distribution Conditions (as such term is defined in the applicable
AREU award documentation for the applicable AREU holder) are met, if ever: (i) Section 5.04 shall hereby be amended to reflect that only net losses as are determined by the General Partner shall be allocable with respect to such AREUs;
(ii) the definition of “Percentage Interest” shall exclude such AREUs solely for purposes of calculating net profits as determined by the General Partner pursuant to Section 5.04; and (iii) Section 6.01 shall not apply
to the AREUs. 
 ARPUs shall be a separate class of units and otherwise shall be identical in all respects to RPUs for all purposes under the
Agreement; except that, for as long as, and until, the Distribution Conditions (as such term is defined in the applicable ARPU award documentation for the applicable ARPU holder) are met, if ever: (i) Section 5.04 shall hereby be
amended to reflect that only net losses as are determined by the General Partner shall be allocable with respect to such ARPUs; (ii) the definition of “Percentage Interest” shall exclude such ARPUs solely for purposes of calculating
net profits as determined by the General Partner pursuant to Section 5.04; and (iii) Section 6.01 shall not apply to the ARPUs. 

APSUs shall be a separate class of units and otherwise shall be identical in all respects to PSUs for all purposes under the Agreement; except
that, for as long as, and until, the Distribution Conditions (as such term is defined in the applicable APSU award documentation for the applicable APSU holder) are met, if ever: (i) Section 5.04 shall hereby be amended to reflect that
only net losses as are determined by the General Partner shall be allocable with respect to such APSUs; (ii) the definition of “Percentage Interest” shall exclude such APSUs 

 
solely for purposes of calculating net profits as determined by the General Partner pursuant to Section 5.04; and (iii) Section 6.01 shall not apply to the APSUs. 

APSIs shall be a separate class of units and otherwise shall be identical in all respects to PSIs for all purposes under the Agreement; except
that, for as long as, and until, the Distribution Conditions (as such term is defined in the applicable APSI award documentation for the applicable APSI holder) are met, if ever: (i) Section 5.04 shall hereby be amended to reflect that
only net losses as are determined by the General Partner shall be allocable with respect to such APSIs; (ii) the definition of “Percentage Interest” shall exclude such APSIs solely for purposes of calculating net profits as determined
by the General Partner pursuant to Section 5.04; and (iii) Section 6.01 shall not apply to the APSIs. 
  

	Section 2.	Creation and Description of PSEs  

Pursuant to the authority conferred on the General Partner under the Agreement, including without limitation Sections 3.01, 4.02, and 13.01 thereof,
there is hereby created a new class of Units in the Partnership designated as PSEs which shall be considered Working Partner Units. 
 PSEs
shall be a separate class of units and otherwise shall be identical in all respects to PSUs for all purposes under the Agreement; except that, the provisions of Section 6.03 (Minimum Distributions in Respect of Restricted Partnership
Units) shall apply to PSEs, as set forth below. 
 For the avoidance of doubt, PSEs shall be counted in the calculation of a Partner’s
Percentage Interest in the event of dissolution of the Partnership (as opposed to RPUs, ARPUs, PSIs and APSIs). 
 The following
Section 6.03 of the Agreement is hereby amended and restated as follows: 
 “Minimum Distributions in Respect of Restricted
Partnership Units and PSEs. Notwithstanding Section 6.01, in no event shall the amount distributed with respect to each Restricted Partnership Unit be less than one-half of a cent ($0.005) with respect to each fiscal quarter (the
“Minimum Distribution Amount” or “MDA”). In the event that the amount that otherwise would have been distributable pursuant to Section 6.01(a)(ii) in respect of such Restricted Partnership Unit (had no MDA applied to such
Restricted Partnership Unit) is less than the applicable MDA for any fiscal quarter or consecutive fiscal quarters, or is negative, the amount distributed to such Working Partner for the next applicable quarter or future quarters during which such
distributable amount exceeds the applicable MDA shall be reduced to the fullest extent possible (but not below the applicable MDA for any such quarter) by an amount equal to such shortfall, until the shortfall has been reduced to zero (0),
provided that, in the event there remains a cumulative shortfall between the aggregate amount of shortfall and the amount by which distributions pursuant to Section 6.01(a)(ii) have been reduced pursuant to this Section, with respect to
Restricted Partnership Units at the time such person becomes a Terminated Partner, the cumulative shortfall shall be applied to reduce (but not below zero (0)) first the Adjusted Capital Account of any Units held by the holder of such Units, then
the Post-Termination Payment applicable to any Units, and thereafter, any other payments in respect of any other Units owed by the Partnership to such Terminated Partner. The General Partner in its sole and absolute discretion shall determine the
characterization for tax purposes of any distribution to a Partner or Terminated Partner pursuant to this Section 6.03 and the impact of such payment, if any, on amounts allocable to and distributable to all Partners under this Agreement.

 Notwithstanding Section 6.01, in no event shall the amount distributed with respect to each PSE be less than one and one-half of a cent
($0.015) with respect to each fiscal quarter (the “Minimum Distribution Amount” or “MDA”). In the event that the amount that otherwise would have been distributable in respect of such PSE (had no MDA applied to such PSE) pursuant
to Section 6.01(a)(ii) is less than the applicable MDA for any fiscal quarter or consecutive quarters, or is negative, the amount distributable to such Working Partner for the next applicable quarter or future quarters during which such
distributable amount exceeds the applicable MDA shall 

 
be reduced to the fullest extent possible (but not below the applicable MDA for any such quarter) by an amount equal to such shortfall, until the shortfall has been reduced to zero (0),
provided that in the event there remains a cumulative shortfall between the aggregate amount of shortfall and the amount by which distributions pursuant to Section 6.01(a)(ii) have been reduced pursuant to this Section, with respect to
PSEs at the time such person becomes a Terminated Partner, the cumulative shortfall shall be applied to reduce (but not below zero (0)) first the Adjusted Capital Account of any Units held by the holder of such Units, and thereafter, any other
payments in respect of any other Units owed by the Partnership to such Terminated Partner; and further provided that the General Partner, however, may determine in its sole and absolute discretion to postpone the payment of any MDA for such
PSE for up to four fiscal quarters. The General Partner in its sole and absolute discretion shall determine the characterization for tax purposes of any distribution to a Partner or Terminated Partner pursuant to this Section 6.03 and the impact of
such payment, if any, on amounts allocable and distributable to all Partners under this Agreement. 
 For the avoidance of doubt, a Partner must
not be a Terminated Partner on the date of payment (whether such payment is a current payment or postponed payment) to be eligible to receive any distribution in respect of such Unit.” 

 

	Section 3.	Definitions 

 The definition of
“Founding/Working Partner” is hereby amended and restated as follows for any Partner who or that becomes a holder of a Working Partner Interest as of (and not before), or at any time after, the effective date of this Amendment: 

“Founding/Working Partner” means any holder of a Founding Partner Interest and/or a Working Partner Interest. Except as
otherwise provided in this Agreement, (a) in the case of a Founding/Working Partner that is a trust, “Founding/Working Partner” shall mean any one or more grantor(s), trustee(s) and/or beneficiar(ies) of such trust, as determined by
the General Partner in its sole and absolute discretion, consistent with the purposes of this Agreement; and (b) in the case of a Founding/Working Partner that is a corporation or other entity, “Founding/Working Partner” shall mean
any one or more shareholder(s) or owner(s) of such entity, as determined by the General Partner in its sole and absolute discretion, consistent with the purposes of this Agreement. 
 The definition of “Working Partner” is hereby amended and restated as follows for any Partner who or that becomes a holder of a Working Partner Interest as of (and not before), or at any time
after, the effective date of this Amendment: 
 “Working Partner” means any holder of a Working Partner
Interest. Except as otherwise provided in this Agreement, (a) in the case of a Working Partner that is a trust, “Working Partner” shall mean any one or more grantor(s), trustee(s) and/or beneficiar(ies) of such trust, as determined by
the General Partner in its sole and absolute discretion, consistent with the purposes of this Agreement; and (b) in the case of a Working Partner that is a corporation or other entity, “Working Partner” shall mean any one or more
shareholder(s) or owner(s) of such entity, as determined by the General Partner in its sole and absolute discretion, consistent with the purposes of this Agreement. 
 The definition of “REU Partner” is hereby amended and restated as follows for any Partner who or that becomes a holder of an REU Interest as of (and not before), or at any time after, the
effective date of this Amendment: 
 “REU Partner” means a holder of REU Interests. Except as otherwise provided
in this Agreement, (a) in the case of an REU Partner that is a trust, “REU Partner” shall mean any one or more grantor(s), trustee(s) and/or beneficiar(ies) of such trust, as determined by the General Partner in its sole and absolute
discretion, consistent with the purposes of this Agreement; and (b) in the case of a REU Partner that is a corporation or other entity, “REU Partner” shall mean any one or more shareholder(s) or 

 
owner(s) of such entity, as determined by the General Partner in its sole and absolute discretion, consistent with the purposes of this Agreement. 

 

	Section 4.	Other Amendments 

 The General
Partner shall have the authority, without the consent of the other Partners other than the Exchangeable Limited Partners (by affirmative vote of a Majority in Interest), to make such other amendments to the Agreement as are necessary or appropriate
to give effect to the intent of this Seventh Amendment, including, without limitation, to amend the Table of Contents or to reflect this Seventh Amendment in an Amended and Restated Agreement of Limited Partnership (and to further amend and/or
restate such Amended and Restated Agreement of Limited Partnership to reflect this Seventh Amendment to the extent necessary or appropriate as determined by the General Partner). 

 Defined terms used herein and not otherwise defined shall have the meanings ascribed to them in the
Agreement. 
  

			
	BGC GP, LLC
		
	By:	 	/s/ Howard W. Lutnick
		 	Name: Howard W. Lutnick
		 	Title: Chairman and CEO
	
	CANTOR FITZGERALD, L.P., as the sole Exchangeable Limited Partner
		
	By:	 	/s/ Howard W. Lutnick
		 	Name: Howard W. Lutnick
		 	Title: Chairman and CEO

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]